Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18).

@article{Scheen2009LongtermGE,
  title={Long-term glycaemic effects of pioglitazone compared with placebo as add-on treatment to metformin or sulphonylurea monotherapy in PROactive (PROactive 18).},
  author={A. J. Scheen and Meng H. Tan and David John Betteridge and K{\aa}re Birkeland and Ole Schmitz and Bernard H Charbonnel},
  journal={Diabetic medicine : a journal of the British Diabetic Association},
  year={2009},
  volume={26 12},
  pages={1242-9}
}
AIMS To assess the long-term glycaemic effects, concomitant changes in medications and initiation of permanent insulin use (defined as daily insulin use for a period of > or = 90 days or ongoing use at death/final visit) with pioglitazone vs. placebo in diabetic patients receiving metformin or sulphonylurea monotherapy at baseline in the PROspective pioglitAzone Clinical Trial in macroVascular Events (PROactive). METHODS In PROactive, patients with Type 2 diabetes and macrovascular disease… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 11 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 21 references

Study (UKPDS) Group

  • UK Prospective Diabete
  • Effect of intensive blood-glucose control with…
  • 1998
Highly Influential
7 Excerpts

Charbonnel B on behalf of the PROactive investigators. Long-term glycaemic control with metforminsulfonylurea- pioglitazone triple therapy in the PROactive Study (PROactive 14)

  • AJ Scheen, MH Tan, DJ Betteridge, K Birkeland, O Schmitz
  • Diabetic Med
  • 2009
2 Excerpts

Similar Papers

Loading similar papers…